After promising Trump new US jobs, Eli Lilly sets out to chop 200 R&D staffers
Eli Lilly is bringing out the corporate ax and aiming it at its R&D operations.
Just weeks after the company announced plans to lay off 485 staffers that had been involved in the failed solanezumab program, the company spread word on Friday that it’s looking for 200 researchers to take a “voluntary exit.”
A spokesperson for Lilly tells me that this amount to about 3% of the company’s total research staff. And the cuts aren’t being aimed at any particular unit.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.